Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that several growth factor receptors consisting of transmembrane and cytoplasmic tyrosine kinase (TK) domains play a vital role in cancer progress...
Main Authors: | Raj Kumar Mongre, Chandra Bhushan Mishra, Arvind Kumar Shukla, Amresh Prakash, Samil Jung, Md Ashraf-Uz-Zaman, Myeong-Sok Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/21/11659 |
Similar Items
-
Novel Carbazole-Piperazine Hybrid Small Molecule Induces Apoptosis by Targeting BCL-2 and Inhibits Tumor Progression in Lung Adenocarcinoma In Vitro and Xenograft Mice Model
by: Raj Kumar Mongre, et al.
Published: (2019-08-01) -
Quo Vadis?
by: Miguel Angelo Padilha
Published: (2024-01-01) -
Prognostic and Clinicopathological Significance of SERTAD1 in Various Types of Cancer Risk: A Systematic Review and Retrospective Analysis
by: Raj Kumar Mongre, et al.
Published: (2019-03-01) -
Quo vadis biofuels?
by: Inderwildi, O, et al.
Published: (2009) -
Aromaticity: quo vadis
by: Merino, G, et al.
Published: (2023)